Alkermes Plc

NASDAQ:ALKSUnited States

Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Contact Information

Headquarters

Connaught HSE, 1 Burlington RoadDUBLIN, Ireland 00000

Phone

---

Fax

---

Executives

Chairman of the Board, Chief Executive Officer

Richard Pops

Interim Chief Financial Officer, Chief Operating Officer, Executive Vice President, Interim Chief Accounting Officer, Chief Risk Officer

Blair Jackson

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

David Gaffin

Executive Vice President, Research and Development and Chief Medical Officer

Craig Hopkinson

Senior Vice President, Chief Commercial Officer

C.Todd Nichols